Pune, India

Puma Chandra Ray

This inventor holds 1 USPTO granted patent. Top assignee: Lupin, Inc.. Active years: 2019.


Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Puma Chandra Ray: Innovator in Pharmaceutical Processes

Introduction

Puma Chandra Ray is a notable inventor based in Pune, India. He has made significant contributions to the field of pharmaceuticals, particularly in the preparation of apremilast and its novel polymorphs. His work is characterized by a focus on improving processes that are both cost-effective and viable at plant scale.

Latest Patents

Puma Chandra Ray holds a patent for the "Process for preparation of apremilast and novel polymorphs thereof." This invention provides an improved method for preparing an intermediate of apremilast. It also introduces novel polymorphs of apremilast, along with pharmaceutical compositions that utilize these polymorphs. The processes he developed are designed to be robust and efficient, enhancing the overall production of apremilast.

Career Highlights

Puma Chandra Ray is associated with Lupin, Inc., a prominent player in the pharmaceutical industry. His work at Lupin has allowed him to focus on innovative solutions that address the challenges in drug formulation and production. His dedication to research and development has positioned him as a valuable asset in the field.

Collaborations

Puma has collaborated with talented coworkers such as Palash Sanphui and Ananda Pundlik Sapdhare. These collaborations have fostered a creative environment that encourages the exchange of ideas and expertise, further enhancing the quality of their work.

Conclusion

Puma Chandra Ray's contributions to the pharmaceutical industry through his innovative processes and collaborations highlight his role as a key inventor. His patent on apremilast preparation showcases his commitment to advancing pharmaceutical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…